YOKNEAM, Israel, May 19, 2025 /PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSC), reported today data of an ...

The collaborators will present positive preclinical data from a study of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small ...

The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral ... Approximately 40% of patients with complete response (CR) and 80% with partial response (PR) experience ...